ARTICLE | Management Tracks
Former J&J exec Mammen sees ‘long-lived’ biotech, succeeds Verdine at Fog
Seeing ‘meaningful’ medicines in pipeline, the Theravance and pharma vet jumps to a well-funded biotech, taking the reins from a leader he knows well
March 30, 2023 10:12 AM UTC
Mathai Mammen’s conviction that FogPharma can become a long-lived biotech company that creates medicines with “totally transformational” impact on patients’ lives fed into his decision to take the top leadership role at that company, succeeding co-founder Greg Verdine.
Verdine will hand off the chairman, president and CEO positions at Fog Pharmaceutical Inc. to Mammen, effective in June, although he’ll remain on the board as vice chairman. The move comes about seven months after Mammen chose to step down as EVP of pharmaceutical R&D at Johnson & Johnson (NYSE:JNJ); he continued to hold the position on an interim basis into early 2023...